{"id":130924,"date":"2026-06-25T12:26:02","date_gmt":"2026-06-25T06:56:02","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=130924"},"modified":"2026-07-03T11:57:03","modified_gmt":"2026-07-03T06:27:03","slug":"mankind-pharma-q1-results-fy27","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/","title":{"rendered":"Mankind Pharma Q1 Results FY27: Date, Revenue Estimates and What to Expect"},"content":{"rendered":"<p><a href=\"https:\/\/univest.in\/user\/log-in\">Get Free Investment Predictions and Mankind Pharma Research at Univest<\/a><\/p><p><a href=\"https:\/\/univest.in\/stocks\/mankind\/mankind-pharma-ltd-share-price-today\">Mankind Pharma<\/a> is expected to announce its Q1 FY27 (April to June 2026) financial results in July or August 2026. This Mankind Pharma Q1 Results FY27 preview covers revenue prediction, Q1 expectations, key catalysts and risks, technical levels and the 12-month analyst price target.<\/p><p>India&#8217;s pharmaceutical and healthcare sector is navigating growth opportunities heading into Q1 Results FY27. The Mankind Pharma Q1 Results FY27 Q1 prediction and Q1 expectations will reflect these sector dynamics.<\/p><p>This Mankind Pharma Q1 Results FY27 Q1 result preview covers Q1 FY27 estimates, Q1 FY26 actual performance for context, key catalysts and risks, and the 12-month analyst price target.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#About_Mankind_Pharma\" title=\"About Mankind Pharma\">About Mankind Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#Mankind_Pharma_Q1_FY27_Estimates_What_to_Expect\" title=\"Mankind Pharma Q1 FY27 Estimates: What to Expect\">Mankind Pharma Q1 FY27 Estimates: What to Expect<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#Key_Catalysts_to_Watch_in_Mankind_Pharma_Q1_Results_FY27\" title=\"Key Catalysts to Watch in Mankind Pharma Q1 Results FY27\">Key Catalysts to Watch in Mankind Pharma Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#1_Domestic_Formulation_Volume_Growth\" title=\"1. Domestic Formulation Volume Growth\">1. Domestic Formulation Volume Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#2_Management_Guidance_for_FY27\" title=\"2. Management Guidance for FY27\">2. Management Guidance for FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#3_Sector_Macro_Commentary\" title=\"3. Sector Macro Commentary\">3. Sector Macro Commentary<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#Key_Risks_for_Mankind_Pharma_Q1_Results_FY27\" title=\"Key Risks for Mankind Pharma Q1 Results FY27\">Key Risks for Mankind Pharma Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#Mankind_Pharma_Q1_FY26_Performance_Setting_the_Context\" title=\"Mankind Pharma Q1 FY26 Performance: Setting the Context\">Mankind Pharma Q1 FY26 Performance: Setting the Context<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#Technical_Analysis_Mankind_Pharma_Share_Price_Levels\" title=\"Technical Analysis: Mankind Pharma Share Price Levels\">Technical Analysis: Mankind Pharma Share Price Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#Mankind_Pharma_Share_Price_Target_Analyst_Estimates\" title=\"Mankind Pharma Share Price Target: Analyst Estimates\">Mankind Pharma Share Price Target: Analyst Estimates<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#Short-Term_Target_3_to_6_Months\" title=\"Short-Term Target (3 to 6 Months)\">Short-Term Target (3 to 6 Months)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#12-Month_Target_Uniresearch_Estimate\" title=\"12-Month Target (Uniresearch Estimate)\">12-Month Target (Uniresearch Estimate)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#Long-Term_View_FY27_to_FY28\" title=\"Long-Term View (FY27 to FY28)\">Long-Term View (FY27 to FY28)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#What_to_Watch_on_Mankind_Pharma_Q1_Results_FY27_Day\" title=\"What to Watch on Mankind Pharma Q1 Results FY27 Day\">What to Watch on Mankind Pharma Q1 Results FY27 Day<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#Frequently_Asked_Questions_on_Mankind_Pharma_Q1_Results_FY27\" title=\"Frequently Asked Questions on Mankind Pharma Q1 Results FY27\">Frequently Asked Questions on Mankind Pharma Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#When_is_Mankind_Pharma_Q1_FY27_results_date\" title=\"When is Mankind Pharma Q1 FY27 results date?\">When is Mankind Pharma Q1 FY27 results date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#What_is_the_Mankind_Pharma_Q1_FY27_revenue_estimate\" title=\"What is the Mankind Pharma Q1 FY27 revenue estimate?\">What is the Mankind Pharma Q1 FY27 revenue estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#What_is_the_Mankind_Pharma_share_price_target\" title=\"What is the Mankind Pharma share price target?\">What is the Mankind Pharma share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#Is_Mankind_Pharma_a_good_buy_before_Q1_FY27_results\" title=\"Is Mankind Pharma a good buy before Q1 FY27 results?\">Is Mankind Pharma a good buy before Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#What_should_I_watch_for_in_Mankind_Pharma_Q1_FY27_results\" title=\"What should I watch for in Mankind Pharma Q1 FY27 results?\">What should I watch for in Mankind Pharma Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27\/#Where_can_I_find_Mankind_Pharma_Q1_FY27_results\" title=\"Where can I find Mankind Pharma Q1 FY27 results?\">Where can I find Mankind Pharma Q1 FY27 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Mankind_Pharma\"><\/span><strong>About Mankind Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Mankind Pharma Q1 Results FY27 will be a critical Q1 result preview for investors. Mankind Pharma is a pharmaceutical and healthcare company listed on the National Stock Exchange and Bombay Stock Exchange. Q1 FY27 (April to June 2026) results will be a key data point for assessing the full-year FY27 earnings trajectory. Any material beat or miss in the Mankind Pharma Q1 Results FY27 Q1 result preview will likely drive meaningful stock price movement.<\/p><p>Mankind Pharma reported Revenue of Rs.3,570 Cr in Q1 FY26, forming the year-on-year comparison base for the Mankind Pharma Q1 Results FY27 estimate. The Mankind Pharma Q1 Results FY27 Q1 expectations point to revenue of Rs.4,222-4,755 Cr.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Mankind_Pharma_Q1_FY27_Estimates_What_to_Expect\"><\/span><strong>Mankind Pharma Q1 FY27 Estimates: What to Expect<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Mankind Pharma Q1 Results FY27 revenue prediction, PAT estimate, results date and 12-month analyst target.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q1 FY27 Estimate<\/strong><\/td><td><strong>Q1 FY26 Actual<\/strong><\/td><td><strong>Context<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs.4,222-4,755 Cr<\/td><td>Rs.3,570 Cr<\/td><td>YoY revenue Q1 result preview<\/td><\/tr><tr><td>PAT \/ Profitability<\/td><td>Rs.321-409 Cr<\/td><td>Rs.445 Cr<\/td><td>Bottom-line Q1 prediction<\/td><\/tr><tr><td>Results Date<\/td><td>July-August 2026 (TBD)<\/td><td>&#8211;<\/td><td>Board meeting Q1 FY27 approval<\/td><\/tr><tr><td>12-Month Target<\/td><td>N\/A<\/td><td>&#8211;<\/td><td>Analyst target \/ Uniresearch estimate<\/td><\/tr><\/tbody><\/table><\/figure><p>Source: Q1 FY26 actuals from company filings. Mankind Pharma Q1 Results FY27 estimates (Q1 prediction) are Uniresearch trailing-growth projections. July 2026. Subject to change.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Catalysts_to_Watch_in_Mankind_Pharma_Q1_Results_FY27\"><\/span><strong>Key Catalysts to Watch in Mankind Pharma Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_Domestic_Formulation_Volume_Growth\"><\/span><strong>1. Domestic Formulation Volume Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>India&#8217;s domestic pharma market is growing at 8-10% annually led by chronic therapies and expanding healthcare access. Analysts will scrutinise management commentary on this point closely during the Mankind Pharma Q1 Results FY27 earnings call. This is a core Q1 prediction metric watched by investors.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Management_Guidance_for_FY27\"><\/span><strong>2. Management Guidance for FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Full-year FY27 revenue and EBITDA margin guidance from the Mankind Pharma management team will be a key determinant of the stock&#8217;s reaction to Q1 Results FY27. Q1 expectations on guidance typically drive 60-70% of post-result price movement for pharmaceutical and healthcare companies.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Sector_Macro_Commentary\"><\/span><strong>3. Sector Macro Commentary<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Management commentary on sector-specific dynamics including demand trends, input cost pressures, and competitive landscape will provide forward guidance visibility. This is one of the key Mankind Pharma Q1 Results FY27 Q1 expectations investors will monitor for sector direction.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Risks_for_Mankind_Pharma_Q1_Results_FY27\"><\/span><strong>Key Risks for Mankind Pharma Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><ul class=\"wp-block-list\"><li>USFDA regulatory warnings or Form 483 observations can disrupt US generic export revenues.<\/li>\n\n<li>Currency volatility and global macro uncertainty can impact revenue from export-facing business segments.<\/li>\n\n<li>Regulatory changes and compliance requirements can increase operating costs.<\/li><\/ul><p><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\">Track Mankind Pharma Q1 Results FY27 Fundamentals on Univest<\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Mankind_Pharma_Q1_FY26_Performance_Setting_the_Context\"><\/span><strong>Mankind Pharma Q1 FY26 Performance: Setting the Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>To understand Mankind Pharma Q1 Results FY27 Q1 expectations, it is important to contextualise Q1 FY26 (April to June 2025) performance. Mankind Pharma reported Q1 FY26 Revenue of Rs.3,570 Cr and PAT of Rs.445 Cr. This provides the year-on-year comparison base against which Mankind Pharma Q1 Results FY27 Q1 expectations will be assessed. Any material beat or miss in the Mankind Pharma Q1 Results FY27 Q1 result preview will likely drive meaningful stock price movement on results day.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Technical_Analysis_Mankind_Pharma_Share_Price_Levels\"><\/span><strong>Technical Analysis: Mankind Pharma Share Price Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><ul class=\"wp-block-list\"><li>Mankind Pharma Q1 Results FY27: Current market price available on NSE portal<\/li>\n\n<li>For the latest 52-week high\/low levels, track Mankind Pharma live on the NSE portal or Univest Screener<\/li>\n\n<li>Mankind Pharma Q1 Results FY27 Q1 expectations: Revenue in the Rs.4,222-4,755 Cr range<\/li>\n\n<li>The stock&#8217;s FY27 trajectory will be shaped by Mankind Pharma Q1 Results FY27 outcome and management guidance<\/li><\/ul><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Mankind Pharma&#8217;s live price, charts and receive SEBI-backed research alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Mankind_Pharma_Share_Price_Target_Analyst_Estimates\"><\/span><strong>Mankind Pharma Share Price Target: Analyst Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Short-Term_Target_3_to_6_Months\"><\/span><strong>Short-Term Target (3 to 6 Months)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In the near term, Mankind Pharma&#8217;s share price will be primarily driven by the Mankind Pharma Q1 Results FY27 outcome relative to estimates. A beat on Revenue or PAT, combined with positive management guidance for FY27, could drive the stock toward the higher end of analyst expectations. Analyst Q1 prediction: a beat on Mankind Pharma Q1 Results FY27 Revenue or PAT could drive the stock higher.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"12-Month_Target_Uniresearch_Estimate\"><\/span><strong>12-Month Target (Uniresearch Estimate)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Mankind Pharma Q1 Results FY27 12-month price target is estimated at available on the Univest research platform. This is contingent on Mankind Pharma Q1 Results FY27 meeting Q1 expectations and FY27 guidance being constructive.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Long-Term_View_FY27_to_FY28\"><\/span><strong>Long-Term View (FY27 to FY28)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Longer-term, the Mankind Pharma Q1 Results FY27 Q1 result preview will anchor the FY27-FY28 outlook. Longer-term, Mankind Pharma&#8217;s share price trajectory will depend on sector growth trends, market share dynamics, management execution quality, and India&#8217;s overall macroeconomic environment.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_to_Watch_on_Mankind_Pharma_Q1_Results_FY27_Day\"><\/span><strong>What to Watch on Mankind Pharma Q1 Results FY27 Day<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><ul class=\"wp-block-list\"><li>Mankind Pharma Q1 Results FY27 Revenue and PAT numbers relative to Q1 Results FY27 estimates of Rs.4,222-4,755 Cr Revenue<\/li>\n\n<li>Mankind Pharma Q1 Results FY27 management guidance: full-year FY27 Revenue and EBITDA margin direction<\/li>\n\n<li>Mankind Pharma Q1 Results FY27 sector-specific operating metrics: domestic formulation volume growth and management guidance<\/li>\n\n<li>Any dividend announcement or capital allocation guidance<\/li>\n\n<li>Management commentary on macro headwinds including USFDA regulatory warnings or Form 483 observations can disrupt US generic export<\/li><\/ul><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Mankind Pharma Q1 Results FY27 is one of the key Q1 result preview events for India&#8217;s pharmaceutical and healthcare sector in the July-August 2026 results season. This Mankind Pharma Q1 Results FY27 Q1 result preview is anchored on Q1 expectations of Rs.4,222-4,755 Cr Revenue. Monitor the Univest research platform for Mankind Pharma Q1 Results FY27 real-time commentary, Q1 predictions and Q1 expectations post the Q1 result preview declaration.<\/p><p>Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice or a stock recommendation. All estimates, analyst targets, and financial projections are based on Uniresearch trailing-growth analysis and are subject to change. Investing in stocks involves market risk. Please consult a SEBI-registered financial advisor before making any investment decision. SEBI RA INH000013776.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Mankind_Pharma_Q1_Results_FY27\"><\/span><strong>Frequently Asked Questions on Mankind Pharma Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_is_Mankind_Pharma_Q1_FY27_results_date\"><\/span><strong>When is Mankind Pharma Q1 FY27 results date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>The Mankind Pharma Q1 FY27 results date has not been officially announced yet. Q1 FY27 (April to June 2026) results are typically declared in July or August 2026. Check the NSE or BSE filing portal for the exact Mankind Pharma Q1 Results FY27 results date.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Mankind_Pharma_Q1_FY27_revenue_estimate\"><\/span><strong>What is the Mankind Pharma Q1 FY27 revenue estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>The Mankind Pharma Q1 Results FY27 revenue prediction (Q1 FY27 estimate) based on Uniresearch trailing-growth analysis is Rs.4,222 to Rs.4,755 Cr. Actual Q1 Results FY27 revenue may differ from this Q1 prediction.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Mankind_Pharma_share_price_target\"><\/span><strong>What is the Mankind Pharma share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>The Mankind Pharma Q1 Results FY27 12-month price target is available on the Univest research platform. Targets are subject to revision based on Q1 Results FY27 outcome.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Mankind_Pharma_a_good_buy_before_Q1_FY27_results\"><\/span><strong>Is Mankind Pharma a good buy before Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>Investing ahead of Mankind Pharma Q1 Results FY27 carries earnings risk. Q1 expectations and Q1 predictions vary, and quarterly results can cause sharp price moves. Assess whether Mankind Pharma offers a good risk-reward at current levels relative to Q1 result preview scenarios. Consult a SEBI-registered financial advisor before any investment decision.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_should_I_watch_for_in_Mankind_Pharma_Q1_FY27_results\"><\/span><strong>What should I watch for in Mankind Pharma Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>Key metrics to monitor for Mankind Pharma Q1 Results FY27 results: Revenue performance versus the Q1 prediction of Rs.4,222-4,755 Cr; PAT versus estimate; management guidance for FY27; domestic formulation volume growth progress; and management commentary on macro headwinds including USFDA regulatory warnings or Form 483 observations can disrupt US generic export.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Where_can_I_find_Mankind_Pharma_Q1_FY27_results\"><\/span><strong>Where can I find Mankind Pharma Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>Mankind Pharma Q1 Results FY27 will be available on the BSE (bseindia.com) and NSE (nseindia.com) filing portals immediately after the board meeting. For real-time analysis, expert commentary, and updated Mankind Pharma Q1 Results FY27 Q1 prediction and Q1 expectations analysis after results are declared, download the Univest app.<\/p>","protected":false},"excerpt":{"rendered":"<p>Mankind Pharma Q1 FY27: Rev Rs 4,444 Cr (+24.5%) PAT Rs 365 Cr (-18.0%) | Uniresearch trailing analysis.<\/p>\n","protected":false},"author":35,"featured_media":130967,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-130924","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1783060030:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["77"],"rank_math_title":["Mankind Pharma Q1 Results FY27: Uniresearch Predictions and Analysis"],"rank_math_description":["Mankind Pharma Q1 Results FY27: Uniresearch projects Q1 FY27 Revenue Rs 4,444 Cr and PAT Rs 365 Cr (Uniresearch trailing analysis). Q4 FY26 actuals inside."],"rank_math_focus_keyword":["Mankind Pharma Q1 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["130967"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["21193"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Mankind-Pharma-Q1-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/130924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=130924"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/130924\/revisions"}],"predecessor-version":[{"id":139127,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/130924\/revisions\/139127"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/130967"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=130924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=130924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=130924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}